Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Journey Medical Corporation
Safety will be assessed through adverse events, blood and urine laboratory tests, physical examination, pulse and blood pressure. Local skin reactions will be assessed including burning/stinging, pruritus, edema, erythema, dryness and scaling.
Age
9–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completed Day 28 of either the DRM04-HH04 or DRM04-HH05 study with at least 80% treatment compliance
Male or females
You may not be if
Subject has a clinically significant abnormality on physical exam, vital signs or ECG at the Week 4 visit of DRM04-HH04 or DRM04-HH05 study that would make further treatment with glycopyrronium contraindicated
Male with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy
Any other condition which, in the judgement of the Investigator, would put the subject at unacceptable risk for participation in the study
Clareo Health | Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
